Awaiting product image

Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments

$1,500.00 – $3,000.00

SKU: KLI4878033 Categories: , Pages: 249

Description

This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc.; vaccines that address these and other not-yet-vaccine-preventable conditions are discussed in Kalorama’s new report, “What’s Next in Vaccines.”
The vaccine industry has seen changes in the past year, and these are covered in this report Vaccines 2012: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high.  The global market for vaccines experienced strong growth in many categories through 2011, declines in others, and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Included in this report are current market size and forecast for the following vaccines:

Pediatric Vaccines:

 

  • Combinations
  • Hepatitis
  • HIB
  • MMR
  • Pneumococcal
  • Poliovirus
  • Varicella
  • Other Pediatric

 

 

Adult Vaccines:

  • Cervical Cancer
  • Hepatitis
  • Influenza
  • Pneumococcal
  • Travel; DT; Misc.

 

 

Kalorama has expanded the global perspective of this report in this edition, including estimates of vaccine sales (pediatric and adult segments) in the following regions:

 

  • U.S.
  • Rest of North Amer.
  • South America
  • Europe
  • Japan
  • India
  • China
  • Rest of World

 

 

Despite ongoing improvements in pediatric vaccination, it is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. This problem is most significant in low income countries, with the health disparity between rich and poor countries resulting in average life spans of about 77 and 52 years, respectively. In addition to this high death toll, millions more suffer disability and illness because they have not been immunized. Adult immunization is an important, but frequently overlooked, part of patient care. Vaccination programs typically focus on children, yet adults in industrialized countries are more likely to die as a result of vaccine-preventable diseases than are children.

Key issues in the global vaccine market today include product safety, refusal to immunize, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems.The following issues are discussed in this report.

 

  • Vaccine Safety
  • Refusal to Immunize
  • Obesity
  • Post-Licensure Surveillance
  • The Future of Vaccine Safety
  • Vaccine Shortages
  • Preventing Pandemics
  • Project Bioshield Act
  • National Bio and Agro-Defense Facility
  • DNA Vaccination
  • Mucosal Delivery
  • Intranasal Delivery
  • Vaccine Patches
  • Vaccine Chips and Microneedles
  • Innovations in Vaccine Production
  • Nanoparticle Systems
  • Cloning

 

 

Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission.For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, immunization rates for these diseases continue to be low in the elderly populations. This report includes profiles of the key players in vaccines, including:

  • AlphaVax, Inc.
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Bharat Biotech
  • Crucell /Johnson & Johnson
  • Emergent biosolutions
  • GlaxoSmithKline
  • Medimmune
  • Merck & Co. Inc
  • Novartis
  • Sanofi Pasteur
  • Pfizer

 

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • The Global Vaccine Industry
    • Scope and Methodology
    • Overview
    • Pediatric Preventative Vaccines
    • The Market
    • Adult Preventative Vaccines
    • The Market
    • Total Market
    • Issues and Trends

CHAPTER TWO: INTRODUCTION TO VACCINES

  • A Brief History: The Development of Vaccines
  • The Immune Response
  • Mechanism of Action
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
    • Genetically Engineered/Modified Vaccines
    • Vaccine Approval Process

CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES

  • Introduction
  • Childhood Immunization in the United States
    • Childhood Immunization Rates
    • Challenges to the Vaccine Delivery System
    • The Effect of U.S. Healthcare Reform
    • Recommended Childhood Immunization Schedule
    • State Immunization Recommendations
    • United Nations Initiatives
  • Pediatric Vaccine Products
    • BCG
    • Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
    • Haemophilus Influenzae Type B
    • Hepatitis A
    • Measles, Mumps and Rubella
    • Meningococcal Disease
    • Pneumococcal Conjugate
    • Rotavirus
    • Varicella
  • Pediatric Vaccines in Development
  • Cost of Vaccines in the United States
  • The World Market for Pediatric Preventive Vaccines
    • Total Market Size and Forecast
    • Hepatitis Vaccine Market
    • Haemophilus Influenzae Type B Vaccine Market
    • Measles, Mumps and Rubella Vaccines
    • Combination Vaccines Market
    • Pneumococcal Vaccine
    • Poliovirus Vaccine
    • Varicella Vaccines
    • Other Vaccines Market

CHAPTER FOUR: ADULT PREVENTIVE VACCINES

  • Introduction
  • Adult Vaccine-Preventable Diseases: Facts and Figures
  • Global Influenza Surveillance Program
    • U.S. Surveillance
  • Recommendations for Adult Immunizations
    • WHO International Health Regulations
  • Adult Vaccine Products
    • Cervical Cancer
    • Cholera
    • Diphtheria-Tetanus
    • Hepatitis
    • Influenza
    • Japanese Encephalitis
    • Pneumococcal Disease
    • Rabies
    • Shingles
    • Typhoid Fever
    • Yellow Fever
  • Adult Vaccines in Development
  • The World Market for Adult Preventive Vaccines
    • Total Market Size and Forecast
    • Cervical Cancer Market
    • Hepatitis Market
    • 1Influenza Vaccine Market
    • Travel, DT, and Miscellaneous Vaccine Market

CHAPTER FIVE: VACCINES MARKET SUMMARY

  • Trends Driving the Vaccines Market
  • Market Size and Forecast
  • Vaccine Sales by Region
  • Vaccine Market Competitors
  • Pediatric Vaccines
  • Adult Vaccines

CHAPTER SIX: ISSUES AND TRENDS

  • Vaccine Safety
  • Refusal to Immunize
  • Obesity
  • Post-Licensure Surveillance
  • The Vaccine Injury Compensation Program
  • World Health Organization
  • Other Initiatives
  • The Future of Vaccine Safety
  • Vaccine Shortages
  • Preventing Shortages in the Developed Countries
  • Preventing Shortages in Developing Nations
  • Preventing Pandemics
  • U.S. National Vaccine Plan
  • Vaccines and Bioterrorism
  • Overview
  • Project Bioshield Act
  • National Bio and Agro-Defense Facility
  • Vaccine Treatment and Evaluation Units
  • Anthrax
  • Smallpox
  • DNA Vaccination
  • Innovations in Vaccine Delivery Systems
  • Mucosal Delivery
  • Intranasal Delivery
  • Vaccine Patches
  • Vaccine Chips and Microneedles
  • Innovations in Vaccine Production
  • Plants
  • Insects
  • Nanoparticle Systems
  • Cloning

CHAPTER SEVEN: COMPANY PROFILES

  • AlphaVax, Inc.
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Bavarian Nordic A/S
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Baxter Healthcare
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Bharat Biotech
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Crucell /Johnson & Johnson
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Emergent biosolutions
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial
  • GlaxoSmithKline
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Medimmune
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Merck & Co. Inc
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Novartis
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Sanofi Pasteur
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information

APPENDIX: COMPANY DIRECTORY

 

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Figure 1-1: World Market for Pediatric Vaccines 2007-2016 Revenues (in millions)
  • Figure 1-2: World Market for Adult Vaccines 2007-2016 Revenues (in millions)

CHAPTER TWO: INTRODUCTION TO VACCINES

  • Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011Exhibit 2-1: Attenuated Virus Production
  • Table 2-2: Vaccine-Preventable Diseases, August 2012
  • Table 2-3: VAERS Table of Reportable Events Following Vaccination

CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES

  • Table 3-1: Global Immunization Rates by Vaccine Type 2010Table 3-2: Immunization Profile of the United States: Population by Age Group, Number of Vaccine-Preventable Diseases Reported by Disease 1990 – 2010
  • Table 3-3: U.S. Recommended Immunization Schedule for Children Ages 0 Through 6 Years, 2012
  • Table 3-4: U.S. Recommended Immunization Schedule for Adolescents Age 7 to 18 Years, 2012
  • Table 3-5: Selected Pediatric Vaccines in Development, August 2012
  • Table 3-6: World Market for Pediatric Vaccines by Type (DTaP/DTP, Hep, HiB, MMR, Combinations, Pneumococcal, Polio, Varicella, Others) 2007-2016 Revenues (in millions)
  • Figure 3-1: Market Share of Pediatric Vaccines by Type 2011
  • Figure 3-2: Market Share of Pediatric Vaccines, by Type 2016
  • Table 3-7: World Market for Pediatric Vaccines by Region (U.S., North America, South America, EU, Japan, India, China, Rest of World) 2006-2015 Revenues
  • Table 3-8: World Pediatric Hepatitis Vaccine Market 2007-2016
  • Table 3-9: World Hib Vaccine Market, 2007-2016
  • Table 3-10: World MMR Vaccines Market 2007-2016
  • Table 3-11: World Combination Vaccines Market 2007-2016
  • Table 3-12: World Pediatric Pneumococcal Vaccine Market 2007-2016
  • Table 3-13: World Poliovirus Vaccine Market 2007-2016
  • Table 3-14: World Varicella Vaccine Market 2007-2016
  • Table 3-15: World Pediatric Other Vaccines Market 2007-2016

CHAPTER FOUR: ADULT PREVENTIVE VACCINES

  • Table 4-1: Universal Adult Immunization Schedule 2012
  • Table 4-2: Summary of Recommendations for Adult Immunization
  • Table 4-3: Initiatives to Require HPV Vaccination by U.S. State, 2012
  • Figure 4-1: U.S. Flu Season Severity from 2002 to 2012
  • Table 4-4: WHO Pandemic Classification Schedule
  • Table 4-5: Selected Adult Preventive Vaccines in Development, 2012
  • Table 4-6: World Market for Adult Preventive Vaccines by Type (Hepatitis, Influenza, Pneumococcal, Travel/DT/Misc.), 2007-2016 Revenues
  • Figure 4-1: Market Share of Adult Vaccines, by Type, 2011
  • Figure 4-2: Market Share of Adult Vaccines, by Type, 2016
  • Table 4-7: World Market for Adult Vaccines by Region (U.S., North America, South America, EU, Japan, India, China, Rest of World) 2007-2016 Revenues
  • Table 4-8: World Cervical CancerVaccine Market 2007-2016
  • Table 4-9: World Hepatitis Vaccine Market 2007-2016
  • Table 4-10: World Influenza Vaccine Market 2007-2016
  • Table 4-11: 2011 Estimated Population by Region and Selected Age Group
  • Table 4-12: World Pneumococcal Vaccine Market 2007-2016
  • Table 4-13: World Travel; Diphtheria-Tetanus; Miscellaneous Vaccines Market 2007-2016

CHAPTER FIVE: VACCINES MARKET SUMMARY

  • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals 2007-2016Table 5-1: The World Vaccines Market by Vaccine Type 2007-2016 Revenues
  • Figure 5-2: World Market for Vaccines Share by Type, 2007, 2011 and 2016
  • Table 5-2: The World Vaccines Market by Region (U.S., North America, SouthAmerica, EU, Japan, India, China, ROW) 2007-2016 Revenues
  • Table 5-3: Major Manufacturers’ Shares of the World Vaccine Market, 2011
  • Figure 5-3: 2011 World Vaccines Market Share, by Leading Competitors
  • Table 5-4: Major Manufacturer’s Shares of the World Pediatric Vaccine Market 2011
  • Figure 5-5: Market Share of Pediatric Vaccines Market, 2011
  • Table 5-5: Major Manufacturer’s Shares of the World Adult Vaccine Market 2011
  • Figure 5-6: Market Share of Adult Vaccines Market 2011

CHAPTER SIX: ISSUES AND TRENDS

Table 6-1: Selected Companies/Laboratories Developing Biodefense Vaccines

 

Related products

The World Market for Transdermal Drug DeliveryMedical Imaging Markets: Molecular Imaging